Characterization of Potassium Channel Modulators with QPatch™ Automated Patch-Clamp Technology: System Characteristics and Performance To cite this article:

雑誌名: ASSAY and Drug Development Technologies
Go to journal
著者: Jonatan Kutchinsky, Søren Friis, Margit Asmild, Rafael Taboryski, Simon Pedersen, Ras K. Vestergaard, Rasmus B. Jacobsen, Karen Krzywkowski, Rikke L. Schrøder, Trine Ljungstrøm, Nathalie Hélix, Claus B. Sørensen, Morten Bech, and Niels J. Willumsen

Planar silicon chips with 1-2-μm etched holes (average resistance: 2.04 ± 0.02 MΩ in physiological buffer, n = 274) have been developed for patch-clamp recordings of whole-cell currents from cells in suspension. An automated 16-channel parallel screening system, QPatch 16, has been developed using this technology. A single-channel prototype of the QPatch system was used for validation of the patch-clamp chip technology. We present here data on the quality of patch-clamp recordings and from actual drug screening studies of human potassium channels expressed in cultured cell lines. Using Chinese hamster ovary (CHO) and human embryonic kidney cells (HEK), gigaseals of 4.1 ± 0.4 GΩ (n = 146) and high-quality whole-cell current recordings were obtained from hERG and KCNQ4 potassium channels. Success rates for gigaseal recordings varied from 40 to 95%, and 67% of the whole-cell configurations lasted for >20 min. Cells were maintained in suspension up to 4 h in a cell storage facility that is integrated in the QPatch 16. No decline in patchability was observed during this time course. A series of screens was conducted with known inhibitors of the hERG and KCNQ4 potassium channels. Dose-response relationship characterizations of verapamil and rBeKm-1 blockage of hERG currents provided IC50 values similar to values reported in the literature.